101 Therapeutics Overview
101 Therapeutics has developed the first-ever targeted glucocorticoid with all of the potency of steroids and none of the systemic toxicities. By targeting the host immune system rather than the pathogen itself, the company can effectively treat a multitude of infectious diseases, whether viral, parasitic, or bacterial.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
CSIR-IICT signs MoU with 101 Therapeutics Israel for new drug for Covid-19
The CSIR-Indian Institute of Chemical Technology (CSIR-IICT) has signed an MoU with 101 Therapeutics Ltd., Israel for clinical trials for a Covid-19 drug. CSIR-IICT will be the knowledge partner for the clinical trial study, offering expert guidance and monitoring. The drug being developed is an intravenous macrophage targeting drug conjugate that aims to kill over-activated macrophages and inactivate the virus in the body. The drug is currently in phase 2 of clinical trials and is expected to be available in India for the treatment of Covid-19 and other infections like meningitis. The agreement between CSIR-IICT and 101 Therapeutics Ltd. is for 3 years.
PartnersCustomers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Seed |
| Rounds | 1 |
| Investors | 1 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | www.101therapeutics.com/ |
Locations
Tel Aviv-Yafo, Israel
Photos & Videos
No files yet
